Apollon Formularies - Result of AGM
Announcement provided by
Apollon Formularies plc · APOL30/12/2022 12:37
30 December 2022
Apollon Formularies Plc
Result of AGM
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a
-ENDS-
For additional information, please visit www.apollon.org.uk or contact:
Apollon Formularies
Tel: +44 771 198 0221
Stene Jacobs stene@apollon.org.uk
Peterhouse Capital Limited (Corporate Adviser)
Tel: +44 207 220 9795
Guy Miller gm@peterhousecapital.com
BlytheRay (Financial PR/IR-London)
Tel: +44 207 138 3204
Tim Blythe/Megan Ray apollon@blytheray.com
About Apollon Formularies and Apollon Formularies Jamaica
Apollon Formularies plc is an international medical cannabis and medicinal mushroom pharmaceutical company headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica since 2016. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to cultivate, perform research and development, process, and sell therapeutic products that include legal medical cannabis to treat various illnesses under medical supervision.
Apollon's proprietary medical cannabis formulations have undergone third-party testing which demonstrated the successful killing of nearly 100% of prostate, triple negative and HER2+ breast cancer cells in 3D cell cultures. Apollon's products are also used to treat patients suffering from different conditions, including chronic pain and epilepsy.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.